Tirzepatide is the first dual-incretin agonist to reach wide use, and its trial
data has reset expectations for the class. This monograph covers the pharmacology
and the evidence.
Chemical identity & structure.
Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at
two receptors: the GLP-1 receptor and the GIP (glucose-dependent insulinotropic
polypeptide) receptor. Structurally it is based on the GIP sequence, modified to
also engage the GLP-1 receptor, and — like semaglutide — it carries a C20 fatty-
acid chain that promotes albumin binding and extends the half-life to roughly 5
days.
Mechanism of action.
Tirzepatide engages both incretin pathways. The GLP-1 component contributes the
appetite-suppression, insulin-secretion, and gastric-emptying effects familiar
from the single-agonist class. The GIP component is the subject of active
research: GIP-receptor agonism is hypothesized to contribute to nutrient
partitioning and to additional appetite effects, though the precise contribution
of the GIP arm in humans is still being characterized.
Key research findings.
The SURPASS program studied tirzepatide in type 2 diabetes and reported strong
glycemic and weight outcomes. The SURMOUNT program studied it for weight
management and documented weight-loss outcomes that exceeded what single-agonist
GLP-1 therapy produced in comparable research. Cardiovascular and other outcome
studies have followed.
The research / citation base.
Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight
management (Zepbound). The SURPASS and SURMOUNT trials are published in major
peer-reviewed journals. Like semaglutide, this is a well-evidenced compound, with
the caveat that it is newer and its long-term record is shorter.
Human clinical trial data.
In the phase 3 SURMOUNT-1 trial (Jastreboff et al., 2022), 2539 adults with obesity received once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period (PubMed).
Quality & sourcing notes.
Tirzepatide's molecular mass is approximately 4814 Da. A credible batch-specific
COA should confirm identity by mass spectrometry and purity by HPLC. As with
semaglutide, counterfeit and underdosed product is a real supply-chain risk;
treat any vial without a matching COA as unverified.
*Research-use note: Educational summary of published research. Tirzepatide is a
prescription drug; this is research context only, not medical advice.*
